A detailed history of Raymond James & Associates transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 46,547 shares of VERA stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,547
Previous 23,221 100.45%
Holding current value
$1.74 Million
Previous $840,000 144.76%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$34.09 - $46.71 $795,183 - $1.09 Million
23,326 Added 100.45%
46,547 $2.06 Million
Q2 2024

Jul 19, 2024

SELL
$33.72 - $48.82 $312,820 - $452,903
-9,277 Reduced 28.55%
23,221 $840,000
Q1 2024

Apr 22, 2024

BUY
$14.91 - $49.14 $79,008 - $260,392
5,299 Added 19.48%
32,498 $1.4 Million
Q4 2023

Jan 16, 2024

SELL
$9.29 - $16.0 $12,504 - $21,536
-1,346 Reduced 4.72%
27,199 $418,000
Q3 2023

Oct 24, 2023

SELL
$13.71 - $19.64 $47,985 - $68,740
-3,500 Reduced 10.92%
28,545 $391,000
Q2 2023

Jul 25, 2023

BUY
$6.11 - $17.83 $41,303 - $120,530
6,760 Added 26.74%
32,045 $514,000
Q1 2023

Apr 14, 2023

BUY
$5.41 - $18.3 $136,791 - $462,715
25,285 New
25,285 $196,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.01B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.